IBRX ▲ +0.7% - ImmunityBio, Inc. $IBRX ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial 09-NOV-2026 06:31 AM ET